Simultaneous quantification of metronidazole, tinidazole, ornidazole and morinidazole in human saliva.
The aim of this study was to develop a rapid and sensitive method for the simultaneous quantification of metronidazole (MEZ), tinidazole (TNZ), ornidazole (ONZ) and morinidazole (MNZ) in human saliva. A reversed-phase high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection at 318 nm was carried out on a C18 column, using a mixture of potassium dihydrogen phosphate buffer, acetonitrile, and methanol (55:15:30, v/v/v) as a mobile phase with a flow rate of 1.0 ml/min. The saliva samples (100 μl) were firstly deproteinized by precipitation with methanol (400 μl), after which they were centrifuged and the supernatants were directly injected into the HPLC system. This method produced linear responses in the concentration ranges of 25.2-5040.0, 23.9-4790.0, 25.4-5080.0, 25.0-5000.0 ng/ml with detection limits of 6.0, 17.6, 10.0 and 11.3 ng/ml for MEZ, TNZ, ONZ and MNZ (S/N=3), respectively. The methods were validated in terms of intra- and inter-batch precision (within 7.3% and 9.1%, respectively), accuracy, linearity, recovery and stability. The study proved that HPLC is both sensitive and selective for the simultaneous quantification of MEZ, TNZ, ONZ and MNZ in human saliva using a single mobile phase.
Research Division of Clinical Pharmacology, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China. wangyq999@yahoo.com.cn
Yongqing
Y
Wang
Peipei
P
Zhang
Ningling
N
Jiang
Xiaojian
X
Gong
Ling
L
Meng
Dewang
D
Wang
Ning
N
Ou
Haibo
H
Zhang
D000900:Anti-Bacterial Agents / Q000032:analysis* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000032:analysis* / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000032:analysis* / Q000627:therapeutic use; D009950:Ornidazole / Q000032:analysis* / Q000627:therapeutic use; D010401:Penicillin G Benzathine; D010510:Periodontal Diseases / Q000188:drug therapy; D012463:Saliva / Q000737:chemistry*; D012680:Sensitivity and Specificity; D014011:Tinidazole / Q000032:analysis* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D009593:Nitroimidazoles; D014011:Tinidazole; D008795:Metronidazole; D009950:Ornidazole; D010401:Penicillin G Benzathine; C547405:morinidazole